Nectar Lifesciences (NSE:NECLIFE) EPS (Basic): ₹-13.41 (TTM As of Mar. 2026)


NSE:NECLIFE Nectar Lifesciences Ltd NSE:NECLIFE
43 GF Score
Price ₹11.42
GF Value ₹6.86
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Nectar Lifesciences EPS (Basic)?

Nectar Lifesciences NSE:NECLIFE -1.04% 43 EPS (Basic) is ₹-13.41 as of Mar. 2026. GuruFocus rates NSE:NECLIFE with a GF Score™ of 43/100 and a GF Value™ of ₹6.86 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Nectar Lifesciences's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was ₹-3.38. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-13.41.

Nectar Lifesciences's EPS (Diluted) for the three months ended in Mar. 2026 was ₹-3.38. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-13.41.

Nectar Lifesciences's EPS without NRI for the three months ended in Mar. 2026 was ₹-1.85. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -4.43.

During the past 3 years, the average EPS without NRI Growth Rate was -3.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Nectar Lifesciences's highest 3-Year average EPS without NRI Growth Rate was 20.70% per year. The lowest was -27.50% per year. And the median was -4.80% per year.

Nectar Lifesciences  (NSE:NECLIFE) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Nectar Lifesciences EPS (Basic) Related Terms

Nectar Lifesciences EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Nectar Lifesciences's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nectar Lifesciences EPS (Basic) Chart

Nectar Lifesciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.12 -1.08 0.22 -5.07 -13.40

Nectar Lifesciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.80 -2.82 -7.85 0.64 -3.38
NSE:NECLIFE
43GF Score
Nectar Lifesciences Ltd NSE:NECLIFE
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nectar Lifesciences EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Nectar Lifesciences's Basic EPS for the fiscal year that ended in Mar. 2026 is calculated as

Basic EPS (A: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-2928.91-0)/218.575
=-13.40

Nectar Lifesciences's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-679.242-0)/200.959
=-3.38

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-13.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of ₹-13.41 mean?
Nectar Lifesciences (NSE:NECLIFE) has a EPS (Basic) of ₹-13.41 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Nectar Lifesciences and its competitors.
Is Nectar Lifesciences' EPS (Basic) too high?
Nectar Lifesciences' current EPS (Basic) is ₹-13.41. Overall, Nectar Lifesciences has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nectar Lifesciences' EPS (Basic) compare to ZTS?
Nectar Lifesciences' EPS (Basic) of ₹-13.41 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Nectar Lifesciences and its competitors. Nectar Lifesciences's current EPS (Basic) is ₹-13.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nectar Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Nectar Lifesciences (NSE:NECLIFE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹6.86, compared to a current price of ₹11.42 — trading 66.5% above its estimated fair value. The current EPS (Basic) is ₹-13.41. Nectar Lifesciences' overall GF Score™ is 43/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Nectar Lifesciences (NSE:NECLIFE), the current EPS (Basic) is ₹-13.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nectar Lifesciences (NSE:NECLIFE) Overvalued in 2026?

Based on GuruFocus' analysis, Nectar Lifesciences stock appears to be overvalued. The current stock price of ₹11.42 is trading 66.5% above its estimated GF Value™ of ₹6.86. GuruFocus considers Nectar Lifesciences to be Significantly Overvalued.

Key valuation signals for NSE:NECLIFE:

  • EPS (Basic): ₹-13.41
  • GF Value™: ₹6.86 vs. price of ₹11.42 (66.5% above fair value)
  • GF Score™: 43/100 with 2 warning signs

No single metric tells the full story. See the NSE:NECLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nectar Lifesciences Business Description

Other Exchanges 532649:India
Address S.C.O. 38-39, Sector 9-D, B-1011/1012, 10th Floor NAURANG HOUSE, Chandigarh, IND, 160009
Nectar Lifesciences Ltd is an India-based pharmaceutical company specializing in Cephalosporins. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products. The Company is also in the Menthol business and succeeded in both domestic and international markets. Its business areas are APIs, Formulations, and Empty Hard Gelatin Capsules. Geographically, it derives a majority of its revenue from India.
43GF Score

Get the complete analysis for NSE:NECLIFE

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹11.42
Price
₹6.86
GF Value